Jim Cramer's Top Stock Picks: PEP CELG GILD REGN BIIB CMG
at The Street - 12 mins ago
Cramer says Chipotle is a huge winner while his 'four horsemen' of Celgine, Gilead Sciences, Regeneron and Biogen Idec are pulling away from the biotech pack.
'Fast Money' Recap: Facebook and Analysts' Expectations
at The Street - 1 hr 12 mins ago
The trading panel discussed why they like Facebook's earnings and why they'd avoid Cheesecake Factory.
The Medicines Patent Pool (MPP) Broadens Collaboration with Gilead Sciences: Signs Licence for Phase III Medicine Tenofovir Alafenamide (TAF)
PR Newswire Europe - Wed Jul 23, 11:31PM CDT
MELBOURNE, Australia, July 24, 2014 /PRNewswire/ --
Gilead Announces New Agreement with Medicines Patent Pool for Access to Medicines in Developing World Countries
Business Wire - Wed Jul 23, 11:00PM CDT
Gilead Sciences, Inc. (NASDAQ:GILD) announced today at the 20th International AIDS Conference in Melbourne, Australia, a new agreement with the Medicines Patent Pool (MPP) to expand access to Gilead's investigational drug tenofovir alafenamide (TAF) for HIV and hepatitis B, contingent on the medicine's U.S. regulatory approval.
Gilead Stock's Great Expectations and Giant Opportunity
Cheryl Swanson, The Motley Fool - Motley Fool - Wed Jul 23, 8:45PM CDT
Today's earnings report from Gilead Sciences , quite simply, knocked it out of the park. Analysts were expecting sales of $2.87 billion for Gilead's hepatitis-C treatment blockbuster Sovaldi. The company handily beat...
Gilead Sciences Crushes Second-Quarter Earnings
George Budwell, The Motley Fool - Motley Fool - Wed Jul 23, 7:30PM CDT
Gilead Sciences reported second-quarter earnings after the bell today, topping consensus for non-GAAP EPS by a noteworthy 31.8% and revenue estimates by 11.4%. Specifically, the company posted non-GAAP EPS of $2.36 on $6.53 billion in revenue. ...
Jim Cramer's 'Mad Money' Recap: Unconventional Wisdom
at The Street - Wed Jul 23, 7:05PM CDT
Should investors settle for average results? Absolutely not, Cramer says.
Gilead profit more than quadruples on hep C drug
AP - Wed Jul 23, 5:59PM CDT
FOSTER CITY, Calif. (AP) — Gilead Sciences Inc. on Wednesday reported profit that more than quadrupled in its second quarter, topping analysts' expectations on sales of its new breakthrough drug for hepatitis C.
Is Gilead About to Crush Pharmacyclics Stock?
Todd Campbell, The Motley Fool - Motley Fool - Wed Jul 23, 5:08PM CDT
Pharmacyclics ' and Johnson & Johnson 's Imbruvica may be one loser following the FDA's approval of Gilead 's Zydelig, or so the story went. However, before investors begin abandoning Pharmacyclics shares thinking that Zydelig will...
Final Glance: Biotechnology companies
AP - Wed Jul 23, 5:02PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Gilead Sovaldi $3.5 Billion: The Most Important Number in Biotech Earnings Season
at The Street - Wed Jul 23, 4:44PM CDT
In its first two quarters on the market, Sovaldi, a pill used to treat hepatitis C, has delivered $5.8 billion in revenue to Gilead. Remarkable.
How Will Gilead Sciences (GILD) Stock Be Affected By Its Second Quarter Earnings Results?
at The Street - Wed Jul 23, 4:24PM CDT
Gilead Sciences (GILD) beat analysts second quarter earnings estimates by 56 cents per share, posting an EPS of $2.36.
Why Do We Watch the Dow Jones So Closely When its Makeup Makes No Sense?
Alex Planes, The Motley Fool - Motley Fool - Wed Jul 23, 3:30PM CDT
The Dow Jones Industrial Average is a strange beast. With only 30 components, it can't possibly represent the scope of American stock markets as well as the broader S&P 500 . Yet not only does the Dow follow the S&P fairly closely in any...
IPO Stock Watch: Biotechs Are Half Of July Calendar
at Investor's Business Daily - Wed Jul 23, 3:07PM CDT
July could see 19 biotechs go public and currently represent 50% of the 34 IPOs scheduled for the next two weeks, according to Renaissance Capital. It's also a sharp spike from the 38 biotech initial public offerings in the first half of the year....
Gilead Sciences Announces Second Quarter 2014 Financial Results
Business Wire - Wed Jul 23, 3:06PM CDT
--- Sovaldi Sales of $3.48 billion -
FDA approves Gilead Sciences drug for 3 cancers
AP - Wed Jul 23, 2:39PM CDT
WASHINGTON (AP) — The Food and Drug Administration on Wednesday approved a new cancer drug from Gilead Sciences Inc. to treat three types of blood cancer.
Biotech Stock Roundup: AbbVie's Tax Inversion, Amgen Drug Scores in Phase 3 - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 23, 1:15PM CDT
AbbVie's (ABBV) agreement to acquire Shire remained the top story in the biotech sector last week.
3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed Jul 23, 1:03PM CDT
I follow a large number of companies, so the usefulness of a watchlist for me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...
Gilead Sciences (GILD) Approaches New Upside Target of $90.59
Comtex SmarTrend(R) - Wed Jul 23, 12:59PM CDT
Gilead Sciences (NASDAQ:GILD) has opened bullishly above the pivot of $89.27 today and has reached the first level of resistance at $89.96. Analysts will be watching for a cross of the next upside pivot targets of $90.59 and $91.91.